Q2 FY2026 EarningsQ2 FY2026 results missed consensus estimates on profitability, with a GAAP EPS of -$0.48 vs. the -$0.375 expected and a net loss of $45.6M vs. the $34.1M consensus. The variance was primarily driven by a surge in G&A expenses to $17.3M, including $10.3M in stock-based compensation related to leadership transitions. Despite the financial miss, the company completed Phase 3 CoMpass trial enrollment and implemented a strategic pivot to ocular oncology, extending its cash runway into 1H 2029.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Aura Biosciences(AURA) the EBIT is -48.07 M (-68%), Miss estimate;the EPS is -0.48 (-2.13%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITMiss expectations
-0.05B68.00%
-0.04B24.98%
-0.01B43.02%
EPSMiss expectations
-0.482.13%
-0.37520.21%
-0.105022.34%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf